Pfizer Inc. (PFE)
NYSE: PFE · Real-Time Price · USD
25.10
-0.07 (-0.26%)
Aug 14, 2025, 12:02 PM - Market open
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
| Oncology | 15.61B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Oncology Growth | 17.69% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 81.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | 40.98% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Business Innovation (Pfizer CentreOne) | 1.15B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Business Innovation (Pfizer CentreOne) Growth | 0.25% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Primary Care | 30.14B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Primary Care Growth | 14.46% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Specialty Care | 16.65B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Specialty Care Growth | 9.27% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 81.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | 40.98% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 81.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | 40.98% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
| Other | 24.94B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| United States | 38.69B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| United States Growth | 26.89% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Developed Markets | 16.06B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Developed Markets Growth | -7.12% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Emerging Markets Revenue (Post-FY2023 Reporting) | 8.88B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Emerging Markets Revenue (Post-FY2023 Reporting) Growth | 8.24% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 24.94B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Developed Europe | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Developed Europe Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Developed Rest of World | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Developed Rest of World Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Emerging Markets | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Emerging Markets Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 24.94B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
| Other | -12.73B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | -48.04% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | -12.73B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | -48.04% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Global Pharmaceuticals Business (Biopharma) Earnings | 28.14B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Global Pharmaceuticals Business (Biopharma) Earnings Growth | 17.50% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Business Activities Earnings | -7.38B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Business Activities Earnings Growth | -9.37% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | -12.73B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | -48.04% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Prevnar Revenue | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Prevnar Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Xeljanz Revenue | 1.17B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Xeljanz Revenue Growth | -24.92% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Vaccines Revenue | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Vaccines Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Ibrance Revenue | 4.37B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Ibrance Revenue Growth | -7.44% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Internal Medicine Revenue | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Internal Medicine Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Inflammation & Immunology Revenue | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Inflammation & Immunology Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rare Disease Revenue | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rare Disease Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Eliquis Alliance Revenue and Direct Sales | 7.37B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Eliquis Alliance Revenue and Direct Sales Growth | 4.95% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Vyndaqel Family Revenue | 5.45B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Vyndaqel Family Revenue Growth | 41.25% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Hospital Revenue | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Hospital Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Comirnaty Direct Sales and Alliance Revenue | 5.35B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Comirnaty Direct Sales and Alliance Revenue Growth | -20.30% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Paxlovid Revenue | 5.72B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Paxlovid Revenue Growth | -772.02% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Prevnar Family Revenue | 6.41B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Prevnar Family Revenue Growth | -1.73% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Nurtec ODT/Vydura Revenue | 1.26B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Nurtec ODT/Vydura Revenue Growth | 27.36% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Abrysvo Revenue | 755.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Abrysvo Revenue Growth | -24.11% |
Log In |
Log In |
Log In |
Log In | Upgrade
|